[
  {
    "ts": "2025-09-20T12:27:15+00:00",
    "headline": "How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval",
    "summary": "In the past week, Incyte announced that the U.S. Food and Drug Administration approved Opzelura (ruxolitinib) cream for the treatment of mild to moderate atopic dermatitis in children as young as two years old, expanding its use beyond previous age restrictions. This milestone significantly increases Opzelura’s potential pediatric patient base and reflects the continued advancement of Incyte’s dermatology portfolio. We'll explore how expanding Opzelura’s pediatric indication could influence...",
    "url": "https://finance.yahoo.com/news/investors-may-respond-incyte-incy-122715153.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f8031405-3b6e-3101-9145-b12bee5e7585",
      "content": {
        "id": "f8031405-3b6e-3101-9145-b12bee5e7585",
        "contentType": "STORY",
        "title": "How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval",
        "description": "",
        "summary": "In the past week, Incyte announced that the U.S. Food and Drug Administration approved Opzelura (ruxolitinib) cream for the treatment of mild to moderate atopic dermatitis in children as young as two years old, expanding its use beyond previous age restrictions. This milestone significantly increases Opzelura’s potential pediatric patient base and reflects the continued advancement of Incyte’s dermatology portfolio. We'll explore how expanding Opzelura’s pediatric indication could influence...",
        "pubDate": "2025-09-20T12:27:15Z",
        "displayTime": "2025-09-20T12:27:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-incyte-incy-122715153.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-incyte-incy-122715153.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]